Solvotrin sets its sights on EIIS funding boost
Established in 2010, Solvotrin Therapeutics is seeking EIIS funding to launch its groundbreaking iron supplement in early 2016.
Its chief executive Pat O’Flynn, a former Ernst & Young Entrepreneur of the Year finalist, said: “Solvotrin Therapeutics’ primary focus is on improving established therapies, making them better and safer with the added advantage of patent protection linked to a defined market need. We are very excited about the high impact of our women’s health ...